Publications - Released in 2015
In this brief, we review drug pricing for new hepatitis C medications and pose basic questions of fairness and medical ethics. Although we focus on Gilead and its hepatitis C drug sofosbuvir, the issues we highlight are broadly applicable to other manufacturers of hepatitis C medications.
Downloads
Organizations
- amfAR (The Foundation for AIDS Research)